The Lewis lab research interests are focused on the development of new PET radiopharmaceuticals for the diagnosis and treatment of cancer. Our work incorporates 89Zr, 18F, 11C, and other nonstandard nuclides, with an emphasis on designing novel PET agents for cancer imaging. Our research program is a molecular-imaging-based program focused on the targeting of nonstandard nuclides as well as the development of small- and biomolecule-based agents and their clinical translation. A few examples of our work are given below.
Jason S. Lewis, PhD
Emily Tow Jackson Chair in Oncology
Research FocusRadiochemist Jason Lewis develops molecular imaging agents for the imaging and therapy of cancer.
EducationPhD, The University of Kent (UK)
- Viola-Villegas NT, Carlin SD, Ackerstaff E, Sevak KK, Divilov V, Serganova I, Kruchevsky N, Anderson M, Blasberg RG, Andreev OA, Engelman DM, Koutcher JA, Reshetnyak YK, Lewis JS. Understanding the Pharmacological Properties of a Metabolic PET Tracer in Prostate Cancer, Proceedings of the National Academy of Sciences (PNAS), 111, 7254-7259, 2014.
- Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko SK, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS*, Thompson CB*. Glutamine Based PET Imaging Facilitates Enhanced Metabolic Evaluation of Gliomas In Vivo. Science Translational Medicine, 7, 274ra17, 2015.
- Berson-Yalow Award, Society of Nuclear Medicine and Molecular Imaging (2013)
- Distinguished Investigator Award from the Academy Radiology Research (2014)
- Fellow, World Molecular Imaging Society (2015)
- SNMMI Michael J. Welch Award (2017)
- Elected Member, International Society for Strategic Studies in Radiology (2017)